EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieMultizentrische StudieOpen Access · CC BY 4.0

Reduction in extraocular muscle and orbital fat volumes after teprotumumab treatment in Japanese patients with thyroid eye disease: an exploratory magnetic resonance imaging analysis from the OPTIC-J trial

Ai Kozaki, Yasuhiro Takahashi, Yuji Tajiri, Zhenxun Wang, Tomoko Hayashida, Ada Kumar, Yuji Hiromatsu, Masashi Mimura

Japanese Journal of Ophthalmology · 2026

DOI: 10.1007/s10384-026-01372-x ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Japanese Journal of Ophthalmology, 2026. Verfasst von Ai Kozaki und 7 weiteren Autor:innen. Beteiligte Einrichtung: Olympia Eye Hospital, 2-18-12 Jingumae, Shibuya-ku, Tokyo, 1500001, Japan. kouzaki@olympia.net. Hauptthemen laut MEDLINE: Adipose Tissue, Graves Ophthalmopathy, Magnetic Resonance Imaging, Oculomotor Muscles. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Amgen Inc.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

This substudy of the OPTIC-J trial analyzed magnetic resonance imaging (MRI) scans from a subset of Japanese patients to examine changes in orbital tissues after teprotumumab treatment vs placebo for active thyroid eye disease (TED). Study design Post hoc exploratory.

Methods

Volumes and inflammation/edema of extraocular muscles (EOMs) and orbital fat were measured before and after 24 weeks of teprotumumab treatment or placebo using MRI in patients enrolled at four of the 16 trial sites. Inflammation/edema in EOM and orbital fat were evaluated using the signal intensity ratio, based on T2 intensity in the cerebral white matter, and an ordinal grading scale (0–3), respectively. Key clinical outcomes included proptosis, diplopia, and clinical activity score (CAS).

Results

Mean (%) changes in total EOM and orbital fat volumes in study eyes treated with teprotumumab ( n = 6) and placebo ( n = 8) were –1,022 mm 3 (–31%; P = 0.007) and –348 mm 3 (–11%; P = 0.039), and –771 mm 3 (–6%; P = 0.120) and 418 mm 3 (4%; P = 0.084), respectively. Reductions were significantly greater with teprotumumab vs placebo (EOM, P = 0.021; fat, P = 0.016). Mean (%) changes in total EOM and orbital fat inflammation/edema grading of study eyes treated with teprotumumab were –1.82 (–31%; P = 0.005) and –1 ( P = 0.031), respectively. Patients administered teprotumumab exhibited improvements in proptosis (83%), diplopia (67%), and resolution of activity determined by CAS (50%).

Conclusion

In this OPTIC-J trial substudy, reductions in orbital soft tissue volumes and inflammation/edema were observed with MRI after teprotumumab treatment vs placebo; corresponding improvements in TED clinical outcomes were also observed.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Adipose TissueGraves OphthalmopathyMagnetic Resonance ImagingOculomotor MusclesOrbitAdultFemaleHumansMaleMiddle AgedDouble-Blind MethodFollow-Up StudiesJapanOrgan SizeTreatment Outcome

Stichwörter der Autor:innen

Clinical trialGraves’ ophthalmopathyImagingInflammationMagnetic resonance imaging

Autor:innen und Institutionen

  • Olympia Eye Hospital, 2-18-12 Jingumae, Shibuya-ku, Tokyo, 1500001, Japan. kouzaki@olympia.net.
  • Department of Oculoplastic, Orbital & Lacrimal Surgery, Aichi Medical University Hospital, Nagakute, Aichi, Japan.
  • Division of Endocrinology and Metabolism, Department of Medicine, Kurume University School of Medicine, Kurume, Fukuoka, Japan.
  • Amgen Inc., Thousand Oaks, CA, USA.
  • Diabetes, Thyroid and Endocrine Center, Shin Koga Hospital, Kurume, Fukuoka, Japan.
  • Oculoplastic Surgery Center, Department of Ophthalmology, Osaka Kaisei Hospital, Yodogawa-ku, Osaka, Japan.

Förderung

  • Amgen Inc

Zitieren

APA

Kozaki, A., Takahashi, Y., Tajiri, Y., Wang, Z., Hayashida, T., Kumar, A., Hiromatsu, Y., & Mimura, M. (2026). Reduction in extraocular muscle and orbital fat volumes after teprotumumab treatment in Japanese patients with thyroid eye disease: an exploratory magnetic resonance imaging analysis from the OPTIC-J trial. Japanese Journal of Ophthalmology. https://doi.org/10.1007/s10384-026-01372-x

Vancouver

Kozaki A, Takahashi Y, Tajiri Y, Wang Z, Hayashida T, Kumar A, et al. Reduction in extraocular muscle and orbital fat volumes after teprotumumab treatment in Japanese patients with thyroid eye disease: an exploratory magnetic resonance imaging analysis from the OPTIC-J trial. Japanese Journal of Ophthalmology. 2026. doi:10.1007/s10384-026-01372-x

BibTeX
@article{Kozaki2026,
  author = {Kozaki, Ai and Takahashi, Yasuhiro and Tajiri, Yuji and Wang, Zhenxun and Hayashida, Tomoko and Kumar, Ada and Hiromatsu, Yuji and Mimura, Masashi},
  title = {Reduction in extraocular muscle and orbital fat volumes after teprotumumab treatment in Japanese patients with thyroid eye disease: an exploratory magnetic resonance imaging analysis from the OPTIC-J trial},
  journal = {Japanese Journal of Ophthalmology},
  year = {2026},
  doi = {10.1007/s10384-026-01372-x}
}
Kostenlos starten →